At a time of annual review and year-end conclusion, a number of major capital market events and award selections have been held intensively, and CMS has received two significant honors. On January 9, at the 2025 Hong Kong Wealth Management Summit and the 12th “Top 100 Hong Kong Listed Companies” Awards Ceremony, CMS was honored as the “Top 100 Hong Kong Listed Companies-Annual Pharmaceutical and Healthcare Innovation Pioneer”. Previously, on December 29, at the 2025 CLS 8th Investment Summit and the “Capital Market Most Value-Influential List” Awards Ceremony, CMS also received the “Most Investment Value Award”. Receiving two authoritative awards in short succession fully demonstrates the market’s high recognition of the Group’s comprehensive strength and long-term development value.
As a highly credible selection event in the Hong Kong stock market, the “Top 100 Hong Kong Listed Companies” aims to identify companies listed on the Main Board with sound development and core investment value. This year’s selection was fully upgraded from previous core evaluation dimensions to focus more on market performance, earnings quality, shareholder returns, and long-term development potential. The judging panel prioritized development resilience and growth quality over mere scale. Specifically, the “Annual Pharmaceutical and Healthcare Innovation Pioneer” award is dedicated to pharmaceutical and healthcare companies with revenues exceeding HKD 2 billion and market capitalizations over HKD 20 billion, comprehensively evaluating their operational effectiveness, industry leadership, and investment value. Similarly, the CLS “Capital Market Most Value-Influential List” uses strategic vision, growth resilience, innovation momentum, and social value as core selection criteria to commend benchmark enterprises leading industry development. Both selections regard development quality and long-term growth potential as vital standards. CMS’s dual awards represent a definitive affirmation of the company’s achievements in building innovation capabilities, optimizing strategic layout, and maintaining steady operations in recent years.
CMS continues to advance its three core strategies: “Product Innovation, Commercial Model Reform, and International Expansion”. The Group is moving steadily along a clear path toward becoming a specialty-focused, innovation-excellent international pharmaceutical enterprise. CMS has built a differentiated, multi-tiered innovative product matrix: 5 products are currently in the commercialization stage, 7 products are in the marketing review stage, and over 10 products are in clinical development stage. In terms of commercialization, while continuously strengthening full-process capabilities in market access, branding, and academic promotion, CMS is deeply tapping into the value of products’ consumer healthcare attributes. By efficiently linking new retail and new media, the Group continues to create incremental value in the broad off-hospital market. In addition, CMS is deepening its full-chain operations—covering R&D, manufacturing, and commercialization—in Southeast Asia and the Middle East regions. Through its secondary listing in Singapore, CMS is accelerating its industrial internationalization process.
Looking ahead, CMS will remain committed to long-termism, consolidating its core competitiveness through innovation-driven growth and steadily advancing high-quality, sustainable development. While continuously improving the accessibility of quality pharmaceutical solutions and addressing unmet medical needs, CMS will further strengthen its operational resilience and value-creation capabilities to deliver stable and sustainable long-term returns to shareholders.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.